Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

Methyltransferase Inhibition Enables Tgf β Driven Induction of CDKN2A and B in Cancer Cells

Abstract 1397: the Regulation of DNMT3B Expression by Lncrna-Ncrms in Cancer

1069 MicroRNA-143 is a Potential Tumor Suppressor Targeting DNA Methyltransferases 3a in Colorectal Cancer

Transcriptional Regulation of Protein Synthesis by Mediator Kinase in MYC-driven Medulloblastoma

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma

Transcriptional Regulation of Protein Synthesis by Mediator Kinase Represents a Therapeutic Vulnerability in MYC-driven Medulloblastoma

An essential role for DNA methyltransferase 3a in melanoma tumorigenesis

542 the Role and Mechanism of KMT2D to Modulate PI3Kα Inhibitor Response in Cervical Cancer Identified by CRISPR/Cas9 Genome-Wide Screening

Knockdown of Methyltransferase-Like 3 in the Prevention of Malignant Progression of Colorectal Cancer by Downregulating Circlmnb1

Data from Downregulation of DNMT3A by Mir-708-5p Inhibits Lung Cancer Stem Cell–like Phenotypes Through Repressing Wnt/β-catenin Signaling

Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer

DMDRMR -Mediated Regulation of m 6 A-Modified CDK4 by m 6 A Reader IGF2BP3 Drives ccRCC Progression

Modulation of the Pol II CTD Phosphorylation Code by Rac1 and Cdc42 Small GTPases in Cultured Human Cancer Cells and Its Implication for Developing a Synthetic-Lethal Cancer Therapy

Enhanced Growth Inhibition by Combined DNA Methylation/hdac Inhibitors in Lung Tumor Cells with Silenced CDKN2A.

Infrequently Methylated Event At Sites-362 To-142 In The Promoter Of Tgf Beta R1 Gene In Non-Small Cell Lung Cancer

TGF-β1 Suppression of Microrna-450B-5p Expression: a Novel Mechanism for Blocking Myogenic Differentiation of Rhabdomyosarcoma

ZNF677 Suppresses Renal Cell Carcinoma Progression Through N6‐methyladenosine and Transcriptional Repression of CDKN3

RNA Interference-Mediated Knockdown of DNA Methyltransferase 1 Leads to Promoter Demethylation and Gene Re-Expression in Human Lung and Breast Cancer Cells

Transforming Growth Factor-Beta (Tgf Beta)-Mediated Growth Inhibition Of Human Myeloid Leukemia Cells Is Cak-Independent But Links To Cdc25c-Cdk1 Pathway

Methyltransferase DNMT3B promotes colorectal cancer cell proliferation by inhibiting PLCG2